Education
About Us
Working with TipRanks
Follow Us
Codexis (CDXS)
NASDAQ:CDXS
CDXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.90 - $6.08
Previous CloseN/A
Volume271.47K
Average Volume (3M)1.15M
Market Cap
$220.25M
Enterprise Value$210.50M
Total Cash (Recent Filing)$66.33M
Total Debt (Recent Filing)$68.98M
Price to Earnings (P/E)―
Beta2.45
Next Earnings
Oct 30, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding90,267,460
10 Day Avg. Volume823,353
30 Day Avg. Volume1,152,844
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue3.68
Enterprise Value/Gross Profit4.74
Enterprise Value/Ebitda-3.93
Forecast
1Y Price Target
$6.33Price Target Upside169.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Balance Sheet ImprovementCodexis was able to improve its balance sheet during the quarter through capital raises of $27.3 million, and at the end of June the company had $66.3 million in cash on hand.
Financial PerformanceCodexis reported better-than-expected financial results for 2Q25, including revenues of $15.3 million, up from $8.0 million in the previous year period, and a reduced net loss of $13.3 million or ($0.16) per share.
Strategic PartnershipsCodexis related that it now has over 30 engagements with ECO Synthesis partners, up from 5-10 at the start of the year, and expects to achieve pilot scale production of GLP-grade siRNA material using the ECO Synthesis Innovation Lab by the end of the year.
Bears Say
Product TransitionAnalyst maintains a Hold rating on CDXS shares as the Company transitions to new products and services and due to the extended period of time before the company's long-range projects mature and begin to create more positive growth metrics.
Codexis News
CDXS FAQ
What was Codexis’s price range in the past 12 months?
Codexis lowest stock price was $1.90 and its highest was $6.08 in the past 12 months.
What is Codexis’s market cap?
Codexis’s market cap is $220.25M.
When is Codexis’s upcoming earnings report date?
Codexis’s upcoming earnings report date is Oct 30, 2025 which is in 42 days.
How were Codexis’s earnings last quarter?
Codexis released its earnings results on Aug 13, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.189 by $0.029.
Is Codexis overvalued?
According to Wall Street analysts Codexis’s price is currently Undervalued.
Does Codexis pay dividends?
Codexis does not currently pay dividends.
What is Codexis’s EPS estimate?
Codexis’s EPS estimate is -0.15.
How many shares outstanding does Codexis have?
Codexis has 90,267,460 shares outstanding.
What happened to Codexis’s price movement after its last earnings report?
Codexis reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.189. Following the earnings report the stock price went up 1.639%.
Which hedge fund is a major shareholder of Codexis?
Currently, no hedge funds are holding shares in CDXS
Codexis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.33 (169.36% Upside)
$6.33 (169.36% Upside)
Insider Transactions
Bought Shares
Worth $777.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.63%
12-Months-Change
Fundamentals
Return on Equity
-111.00%
Trailing 12-Months
Asset Growth
4.73%
Trailing 12-Months
Company Description
Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
CDXS Company Deck
CDXS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Codexis, with significant revenue growth, improved margins, and strong demand for the ECO Synthesis platform. However, the company faces challenges in revenue predictability and increased R&D expenses.View all CDXS earnings summariesCDXS Stock 12 Month Forecast
Average Price Target
$6.33
▲(169.36% Upside)
Technical Analysis
Foghorn Therapeutics
―
Inhibikase Therapeutics
―
Atea Pharmaceuticals
―
Terns Pharmaceuticals
―
Nuvectis Pharma
―
Ownership Overview
16.55% Insiders
17.31% Mutual Funds
39.67% Other Institutional Investors
17.50% Public Companies and
Individual Investors